Journal
TRENDS IN MICROBIOLOGY
Volume 31, Issue 4, Pages 393-404Publisher
CELL PRESS
DOI: 10.1016/j.tim.2022.11.001
Keywords
-
Categories
Ask authors/readers for more resources
Antiretroviral therapy (ART) is effective in reducing HIV-1 infection. However, the emergence of treatment-refractory variants remains a challenge. HIV-1 uses cellular helicases, including DDX3X, to facilitate its replication. Exploring these helicases may reveal new therapeutic targets and help prevent viral escape.
Antiretroviral therapy (ART) reduces human immunodeficiency virus type 1 (HIV-1) infection, but selection of treatment-refractory variants remains a major chal-lenge. HIV-1 encodes 16 canonical proteins, a small number of which are the singular targets of nearly all antiretrovirals developed to date. Cellular factors are increasingly being explored, which may present more therapeutic targets, more effectively target certain aspects of the viral replication cycle, and/or limit viral escape. Unlike most other positive-sense RNA viruses that encode at least one helicase, retroviruses are limited to the host repertoire. Accordingly, HIV-1 subverts DEAD-box helicase 3X (DDX3X) and numerous other cellular helicases of the Asp-Glu-x-Asp/His (DExD/H)-box family to service multiple aspects of its replication cycle. Here we review DDX3X and other DExD/H-box helicases in HIV-1 replication and their inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available